Hi Golf_Nut!
You know as bailie wrote most Vidaza studies contain high risk patients. Here are two abstracts - both on high risk patients - about oral Vidaza. The adverse effects are probably the same in high and low risk patients even if low risk patients can tolerate them better.
http://www.bloodjournal.org/content/122/21/1554
https://ash.confex.com/ash/2014/webp...aper71118.html
As you can see they write in the first abstract that a Phase III study of extended oral azacitidine dosing is ongoing in lower-risk MDS patients.
Kind regards
Birgitta-A